Milestone Pharmaceuticals

113 articles about Milestone Pharmaceuticals

• Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference - June 1, 2023

  6/1/2023

  Milestone Pharmaceuticals Inc. today announced that members of its management team will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 a.m. ET.

• Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

  5/22/2023

  Milestone Pharmaceuticals Inc. today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

• Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

  5/11/2023

  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2023, and provided a clinical and corporate update.

• Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

  5/8/2023

  Milestone Pharmaceuticals Inc. today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET.

• Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

  4/12/2023

  Milestone Pharmaceuticals Inc. today announced that members of its management team will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023.

• Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update

  3/29/2023

  Milestone Pharmaceuticals Inc. today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a clinical and corporate update.

• Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT

  3/28/2023

  Milestone Pharmaceuticals Inc. announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates.

• Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia

  3/6/2023

  Milestone Pharmaceuticals Inc. today announced significant progress in clinical and regulatory activities for etripamil, the Company's investigational calcium channel blocker that is administered by patients outside of the healthcare setting to treat paroxysmal supraventricular tachycardia (PSVT).

• Milestone Pharmaceuticals to Present at Upcoming March 2023 Investor Conferences

  2/28/2023

  Milestone Pharmaceuticals Inc. announced that members of its management team will present at the following investor conferences.

• Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT

  11/29/2022

  Milestone Pharmaceuticals Inc. today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET.

• Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

  11/22/2022

  Milestone Pharmaceuticals Inc.  today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.

• Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update

  11/10/2022

  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2022, and provided a clinical and corporate update.

• Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022

  11/7/2022

  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting.

• Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray

  10/25/2022

  Milestone Pharmaceuticals Inc. today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually.

• Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

  10/17/2022

  Milestone Pharmaceuticals Inc. announced positive topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia.

• 

  Milestone Gears Up to Submit Tachycardia Nasal Spray to Regulators

  10/17/2022

  Milestone Pharmaceuticals reported highly positive data from its Phase III RAPID trial of etripamil in paroxysmal supraventricular tachycardia (PSVT) patients. 

• Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Milestone Pharmaceuticals Inc. announced that Joseph Oliveto, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:00 p.m. ET in New York, NY.

• Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update

  8/10/2022

  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2022, and provided a clinical and corporate update.

• Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference

  6/2/2022

  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference.

• Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 27, 2022

  5/27/2022

  Milestone Pharmaceuticals Inc. announced that Milestone's Compensation Committee granted three new employees incentive stock options to purchase an aggregate of 92,000 common shares, at a per share exercise price of $5.48, the closing price of Milestone's common stock on May 16, 2022.